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To evaluate hemodynamic effectiveness and physiologic changes on the HeartMate 1000 
IP left ventricular assist device (Thermo Cardiosystems, Inc., Woburn, Mass.), we 
studied 25 patients undergoing bridge to heart ransplantation (35 to 63 years old, mean 
50 years). All were receiving inotropic agents before left ventricular assist device 
implantation, 21 (84%) were supported with a balloon pump, and 7 (28%) were 
supported by extracorporeal membrane oxygenation. Six patients died, primarily of 
right ventricular dysfunction and multiple organ failure. Nineteen (76%) were rehabil- 
itated, received a donor heart, and were discharged (100% survival after transplanta- 
tion). Pretransplantation duration of support averaged 76 days (22 to 153 days). No 
thromboembolic events occurred in more than 1500 patient-days of support with only 
antiplatelet medications. Significant hemodynamic improvement was measured (before 
implantation to before explantation) in cardiac index (1.7 -+ 0.3 to 3.1 -- 0.8 L/min per 
square meter; p < 0.001), left atrial pressure (23.7 ± 7 to 9 -+ 7.5 mm Hg; p < 0.001), 
pulmonary artery pressure, pulmonary vascular resistance, and right ventricular 
volumes and ejection fraction. Both creatinine and blood urea nitrogen levels were 
significantly higher before implantation i patients who died while receiving support. 
Renal and liver function returned to normal before transplantation. We conclude that 
support with the HeartMate device improved hemodynamic and subsystem 
function before transplantation. Long-term support with the HeartMate device has a 
low risk of thromboemboli and makes a clinical trial of a portable HeartMate device a 
realistic alternative to medical therapy. (J THORAC CARDIOVASC SURG 1995;109:409-18) 
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T he implantable left ventricular assist device (LVAD) is currently being used as a bridge to 
heart transplantation. However, a new clinical trial 
with the portable HeartMate LVAD (Thermo Car- 
diosystems, Inc., Woburn, Mass.) should begin soon. 
In this multicenter trial, the HeartMate LVAD will 
not be used for patients awaiting transplantation, 
but as an alternative to medical therapy for patients 
with end-stage heart disease who are not candidates 
for transplantation or other surgical therapy. This 
trial will be the first clinical use of mechanical 
circulatory support devices as permanent herapy 
since the very early use of the pneumatic Jarvik 7 
total artificial heart (Symbion Inc., Salt Lake City, 
Utah) J  
To better understand the hemodynamic and phys- 
iologic changes seen during implantable LVAD 
support, we carefully studied Cleveland Clinic pa- 
tients who underwent HeartMate 1000 IP pneu- 
matic LVAD support as a bridge to heart transplan- 
tation. This article reports our experience and 
observations regarding hemodynamic and physio- 
logic changes during LVAD support, changes ob- 
served in the left and right ventricles, and improve- 
ment in patient exercise capacity. 
Patients and methods 
Twenty-five consecutive patients received the pneumat- 
ically driven HeartMate LVAD according to a protocol. 
The devices were implanted between December 1991 and 
March 1994. The mean age of the patients was 50 years 
(range 35 to 63 years) and 21 were men (84%). Seven of 
the patients had dilated cardiomyopathy and 18 patients 
(72%) had ischemic cardiomyopathy. The group with 
ischemic ardiomyopathy included 10 patients who had 
acute myocardial infarctions within 2 weeks of LVAD 
implantation. Twenty-one patients met inclusion and ex- 
clusion guidelines for the experimental device according 
to the Food and Drug Administration (FDA) criteria. 2
Four patients were clear deviations flora the FDA proto- 
col because of recent myocardial infarctions within I week 
of LVAD implantation without preexisting cardiomyopa- 
thy (acute myocardial infarction <7 days before LVAD 
insertion was a FDA exclusion criterion). All patients (of 
their family members) gare informed consent o LVAD 
insertion, and the trial was carried out with the approval 
of the Cleveland Clinic Institutional Review Board. 
The HeartMate 1000 IP is a pneumatically driven 
pusher plate LVAD with pump inflow ffom the left 
ventricular apex and pump outflow to the ascending aorta. 
Descriptions of the device 2and implantation techniques 3 
have been previously published. The device was implanted 
in a pocket in the left upper quadrant of the abdominal 
wall underneath t e left rectus muscle and on top of the 
posterior ectus fascia in all patients except the first 
patient (intraabdominal implantation was used). 3 All 
LVADs were placed in the automatic mode after the 
patient was weaned from cardiopulmonary b pass, so that 
the pump automatically ejected when 90% full. 4 Typically, 
the left ventricle is unloaded in this mode of operation 
and the patient's aortic valve does not open during 
ventricular systole. 
All patients were in severe cardiogenic shock as part of 
the FDA inclusion criteria, and many were moribund. All 
patients were receiving inotropic support. Twenty-one 
patients (84%) were also receiving intraaortic balloon 
pump (IABP) support. An IABP was not plaeed because 
of tachycardia n one patient (heart rate 150 beats/min) 
and bacteremia during two previous IABP insertions in 
another patient. Twenty patients (80%) were intubated 
for pulmonary edema. Nine patients (36%) had under- 
gone previous coronary artery bypass. Seven patients 
(28%) were in such severe acute cardiogenic shock that 
they had to be supported with a heparin-coated xtracor- 
poreal membrane oxygenator (ECMO) to stabilize their 
condition and allow evaluation and clearance as trans- 
plantation candidates (an important prerequisite before 
HeartMate LVAD insertion). 
Multiple hemodynamic measurements were made: (1) 
in the operating room before LVAD insertion; (2) after 
LVAD insertion after weaning from cardiopulmonary 
bypass, (3) 24 hours after LVAD insertion, and (4) weeks 
later, just before LVAD explantation and heart ransplan- 
tation. Left atrial pressure was measured irectly before 
LVAD insertion and explantation and was monitored 
continuously with a percutaneous catheter for at least 24 
hours after insertion. Transpulmonäry gradient was mea- 
sured (mean pulmonary artery pressure - mean left atrial 
pressure) and divided by cardiac output to determine 
pulmonary vascular esistance in Wood units. A special 
fast-response thermodilution pulmonary artery catheter 
(REF catheter, Baxter Healthcare Corp., Irvine, Calif.) 
was used to calculate right ventricular end-diastolic vol- 
urne, right ventricular end-systolic volume, right ventricu- 
lar stroke volume (end-diastolic volume - end-systolic 
volume), right ventricular stroke work index, and right 
ventricular ejection fraction. The right ventricular ejection 
fraction was correlated with the right ventricular "frac- 
tional area of change," an equivalent measurement to
right ventricular ejection fraction, by means of intraoper- 
ative echocardiographic techniques with automatic 
boundary detection via acoustic quantification. 5'6 The 
REF catheter and echocardiographic studies provided two 
independent measurements of right ventricular function. 
Hypoxemia nd acidosis were assiduously avoided in 
the early postoperative phase because of their deleterious 
effects on the pulmonary resistance and subsequently right 
heart function. Patients' lungs were ventilated to maintain 
arterial oxygen tension greater thän 100 mm Hg, carbon 
dioxide tension approximately 30 mm Hg, and lowest 
possible peak inspiratory pressures (typically high-rate, 
low tidal volume ventilation). 
Laboratory values considered baseline were obtained 
within 24 hours of LVAD insertion. Laboratory values 
were repeated at least weekly while the patients were 
receiving LVAD support and within hours before LVAD 
explantation and heart ransplantation. Treadmill exereise 
began shortly after the patients having an LVAD were 
transferred out of the intensive care unit. The recorded 
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treadmill distance underestimated the patient's activity 
level because patients also were ambulating throughout 
the hospital and grounds, and some minimally super- 
vised additional treadmill exercise sessions were not 
recorded. 
No heparin or warfarin was given for pump anticoagu- 
lation. Intraoperative heparin was reversed with prota- 
mine after the patient was weaned from cardiopulmonary 
bypass. Perioperative aprotinin was given to 20 patients. 
Dextran was not administered to any patients after the 
operation. One patient had a short course (<5 days) of 
intravenous heparin for deep vein thrombosis until a vena 
cava filter was placed. Only antiplatelet agents were given 
for pump anticoagulation, consisting of one aspirin per 
day (350 mg) and 75 mg of dipyridamole 3 times a day. 
Ten patients completed pump support without any anti- 
coagulants (including antiplatelet agents) because of pep- 
tic ulcer disease or other clinical concerns. 
Percent change from baseline was analyzed with either 
a paired t test or Wilcoxon signed rank test as appropriate. 
Significance l vels of 0.05 or less were considered to be 
statistically significant. A Wilcoxon rank sum test was used 
to compare baseline values for patients who survived until 
transplantation versus patients who died before transplan- 
tation. All values are expressed as mean plus or minus 
standard eviation unless otherwise stated. 
Results 
Of the 25 patients, 19 (76%) underwent trans- 
plantation, including five of seven (71%) who re- 
quired ECMO support before LVAD insertion and 
17 of 21 (81%) of those who met all FDA inclusion/ 
exclusion criteria. The mean duration of LVAD 
support was 63 days (range 0.2 to 153 days); it was 76 
days (range 22 to 153 days) for those who underwent 
transplantation. 
Six patients died during LVAD support (Table I), 
most of progressive multiple organ failure despite 
adequate LVAD flow. Autopsies were obtained in 
all patients. One patient who died had undergone 
urgent reoperative myocardial revascularization, 
complicated by cardiac arrest. The patient was sup- 
ported by ECMO after this operation for 20 hours 
but with hypotension despite adequate flow. Urgent 
HeartMate LVAD insertion led to initially adequate 
flows but persistent hypotension. The patient died 
shortly after return to the intensive care unit, and 
autopsy confirmed what was by then our clinical 
suspicion, extensive cerebral hemorrhage. Two 
other patients had severe coagulopathy, eventually 
required a right ventricular assist device (RVAD) 
for high pulmonary vascular resistance, had multiple 
organ failure, and died. In one of these patients the 
RVAD was successfully removed, with good hemo- 
dynamics, but late Candida mediastinitis contrib- 
uted to the patient's death. Three other patients had 
Table I. Patient deaths during LVAD support 
Age Duration 
Patient (yr) Diagnosis (days) PI Comments 
1 61 ICM 44 3.6 RVAD, Candida, 
MOF 
2 53 ICM 3 2.1 RVAD, coagulopathy, 
MOF 
3 35 ICM 70 2.5 RHF, Candida, MOF 
4 48 ICM 13 3.1 RVAD-ECMO, MOF 
5* 63 ICM 0.2 1.9 Intracerebral b eed 
6* 46 AMI 12 2.0 MOF 
PI, Pump index on support (L/min per square meter); ICM, ischemic 
cardiomyopathy; DCM, dilated cardiomyopathy; AMI, acute myocardial 
infarction; RVAD, right ventricular ssist device; MOF, multiple organ 
failure; RHF, persistent right heart failure; ECMO, extracorporeal mem- 
brane oxygenation. 
*Patients having pre-LVAD ECMO and FDA exclusions. 
progressive multiple organ failure, one required 
RVAD support, and another had chronic right 
ventricular dysfunction such that the inotropic med- 
ications could not be stopped during 70 days of 
LVAD support. None of the patients who died ever 
left the intensive care unit or were able to be 
extubated. 
In total, four patients (16%) required RVAD 
support. These four include two with heparin-coated 
RVAD-ECMO systems, returning oxygenated blood 
to the pulmonary artery in one patient and to the left 
atrium in the other. One patient, who was supported 
by ECMO before insertion of the LVAD, was hypox- 
emic after being weaned from cardiopulmonary bypass 
with LVAD support, and this contributed to right 
heart failure. An RVAD-ECMO system was placed, 
and a bronchoscopic examination showed that she had 
aspiration of gastric contents (probably when intu- 
bated during a cardiac arrest he day before). She was 
treated with antibiotics, her lungs improved, and the 
RVAD-ECMO system was removed. The patient re- 
covered and underwent successful transplantation af-
ter 143 days of support. The three other patients 
requiring an RVAD all died of multiple organ failure, 
although two RVADs were removed. 
Hemodynamic hanges with the initiation of 
LVAD pumping were seen immediately. The 
changes in this report are described from the left 
heart first, then pulmonary artery pressures, and 
then right heart changes. 
The cardiac index before LVAD insertion was low 
(1.67 _+ 0.3 L/min per square meter) and the left 
atrial pressure was high (Table II, Fig. 1). A signif- 
icant rapid increase in cardiac index ("pump" index 
from the device 4) and an immediate decrease in left 
atrial pressure were seen in the operating room after 
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Fig. 1. The cardiac index (CI) before LVAD insertion (pre-implant) was low (1.7 _+ 0.3 L/min per square 
meter) in these patients with cardiogenic shoek. In the operating room during LVAD support (post- 
implant), the cardiac index rose to 3.1 L/min per square meter and stayed at approximately this level at 24 
hours and for the duration of support until the time of device explantation and transplantation 
(pre-explant). The left atrial pressure (LAP) dropped from 23 mm Hg to 10 mm Hg with the initiation of 
LVAD pumping and stayed low at 24 hours and pre-explant. Right atrial pressure (RAP) dropped gradually 
from a mean of 20 mm Hg down to 12 mm Hg before device explantation and transplantation. 
Table II. Hemodynamic changes during LVAD support 
p Value p Value 
pre-LVAD vs pre-LVAD vs 
Pre-L VAD Post-L VAD post-L VAD 24 hr Pre-explant pre-explant 
CI 1.7 -+ 0.3 (1.7) 3.1 -+ 1.0 (3.1) p < 0.0001 3.1 + 0.6 (3.0) 3.1 + 0.8 (2.8) p < 0.0001 
LA 23.1 + 7.1 (22) 10.4 ± 4.7 (11) p < 0.001 13.0 + 4.5 (13) 9.0 + 7.5 (8) p < 0.001 
PA sys 52.5 + 13.9 (50) 40.0 + 12.1 (37) p = 0.003 36.2 - 10.4 (35) 30.2 + 9.4 (28) p < 0.0001 
PA mean 38.5 ± 7.9 (38) 28.7 + 7.7 (28) p < 0.0001 28.9 - 9.5 (27) 21.6 ± 7.7 (20) p < 0.0001 
PAD 30.2 _+ 8.2 (29.5) 21.2 ± 7.2 (21) p < 0.0001 22.5 + 9.3 (21) 15.0 + 6.7 (14) p < 0.0001 
TPG 14.5 + 7.6 (14) 18.3 + 8 (17) p = 0.05 15.3 --- 8.6 (14) 11.7 -+ 5.1 (10) p = 0.30 
PVR 4.4 -- 2.7 (3.8) 3.5 + 2.2 (2.9) p = 0.16 3.0 ± 2.5 (2.6) 2.2 _+ 1.1 (1.8) p = 0.001 
RVEF 16.5 + 9.3 (16.5) 31.6 _+ 9.4 (33) p < 0.0001 29.2 ± 10.3 (27.5) 38.1 ± 14.5 (41) p < 0.0001 
RVAQ 21.6 ± 9.6 (20.4) 35.4 ± 11.6 (34) p < 0.0001 NA 43.5 -+ 9.7 (44) p < 0.0001 
RVEDV 302 ± 178 (226) 221 ± 78 (202) p = 0.06 243 ± 103 (211) 174 ± 74 (151) p = 0.002 
RVESV 266 ± 178 (189) 142 ± 77 (135) p = 0.002 184 ± 98 (152) 110 ± 65 (87) p = 0.001 
RVSWI 4.7 _+ 2.4 (4.3) 5.3 ± 3.5 (5.6) p = 0.93 4.4 + 2.6 (3.9) 4.2 ± 3.1 (3.5) p = 0.19 
RA 20.1 ± 6.4 (21) 16.9 ± 6.4 (17) p = 0.07 15.3 ± 3.8 (15) 12.3 ± 6.2 (12) p < 0.0001 
All values are expressed as mean -+ standard eviatiorl (median). C/, cardiac index (or pump index on LVAD) (L/min per square meter); LA, left atrial 
pressure (mm Hg); PA sys, pulmonary artery systolic pressure (mm Hg); PAz~ PA diastolic pressure (mm Hg); TPG, transpulmonary g adient (mm Hg); PFR, 
pulmonary vascular resistanee (Wood units); RVEF, right ventricular ejection fraction (%); RVAQ, right ventricular acoustic quantification area of change 
(%); RVEDV/RVESV, right ventricular end-diastolic/end-systolic volumes (ml); RVSWL, right ventricular stroke work index (5-10 gm/m 2per beat); RA, right 
atrial pressure (mm Hg); NA, not available. 
the start of LVAD flow. The cardiac index and left 
atrial pressure remained virtually normal at 24 hours 
and when measured before explantation. 
The pulmonary artery pressures were elevated 
before LVAD insertion, consistent with severe heart 
failure. The pulmonary artery pressures rapidly de- 
creased (Fig. 2) with LVAD pumping and the 
decrease in left atrial pressure. For example, the 
pulmonary artery diastolic pressure decreased from 
30.2 _+ 8.2 mm Hg before LVAD insertion to 21.2 _+ 
7.2 mm Hg after LVAD insertion, 22.5 -+ 9.3 mm 
Hg at 24 hours, and 15.0 + 6.7 mm Hg at LVAD 
explantation. The transpulmonary gradient showed 
an interesting transient increase that has been in- 
ferred 7 but not documented. The transpulmonary 
gradient increased (p = 0.046) after LVAD inser- 
tion (Fig. 3), most likely because of a combination of 
the effects of cardiopulmonary bypass and blood 
product administration on the pulmonary bed and a 
delay as the lungs clear the pulmonary edema 
present before LVAD insertion. By 24 hours the 
transpulmonary gradient had returned to baseline 
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and was lower, but not significantly so (p = 0.29), at 
explantation. 
Pulmonary vascular esistance was elevated be- 
fore LVAD insertion (4.4 _+ 2.7 Wood units) and 
decreased with LVAD pumping (Table II), despite 
the early increase in transpulmonary gradient, be- 
cause of a much higher cardiac output. Pulmonary 
vascular esistance gradually decreased (3.5 _+ 2.2 
Wood units after LVAD insertion, 3.0 ___ 2.5 Wood 
units at 24 hours) a,ad reached a typical level for 
heart ransplant recipients (2.2 ___ 1.1 Wood units) at 
the time of LVAD explantation. 
Changes in the right side of the heart mirrored 
the changes in pulmonary artery pressures and 
pulmonary vascular esistance, further supporting 
the conclusion of most investigators that right heart 
function during LVAD support is primarily deter- 
mined by right ventricular afterload. 7-9 The right 
ventricle was markedly dilated in most patients and 
decreased in volume (both end-systolic and end- 
diastolic volume) during LVAD pumping (Fig. 4). 
The right ventricular ejection fraction also steadily 
increased (see Table II) and correlated weil with 
right ventricular acoustic quantification (obtained 
independently by transesophageal echocardiogra- 
phy during the operation and at LVAD explanta- 
tion). Studies are ongoing with right ventricular 
Millar catheters (Millar Instruments, Inc., Houston, 
Tex.) to determine right ventricular pressure-vol- 
ume loops. However, our only other measure of 
right ventricular contractility, right ventricular 
stroke work index, showed no intrinsic change in 
right ventricular function. Right ventricular stroke 
work index was low and stayed low (Table II) in the 
early period and before explantation (all p > 0.05). 
Finally, right atrial pressure, which was elevated at 
baseline (20.1 -+ 6.4 mm Hg), gradually decreased 
(see Fig. 1) to near normal before LVAD explanta- 
tion (12.3 + 6.2 mm Hg). 
We could not identify any preoperative factors in 
the four patients who required RVAD support hat 
would indicate that they were at particularly high 
risk to need RVAD support. Pre-LVAD transpul- 
monary gradients were 17, 8, 7, and 16 mm Hg for 
these four patients. The pulmonary vascular esis- 
tances were 3.5, 3.6, 7.0, and 5.2 Wood units, and 
right ventricular ejection fractions were 17%, 9%, 
and 18% (one not available). 
Because most deaths eventually were related to 
multiple organ failure, we analyzed renal and he- 
patic function at baseline and during support. Liver 
dysfunction was common before LVAD insertion, 
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Fig. 2. Pulmonary artery (PA) pressures were elevated in 
these patients with severe congestive heart failure. The 
pressures dropped immediately after the start of LVAD 
pumping and showed a further decrease by the time of 
device xplantation. 
with a mean total bilirubin value of 2.9 _+ 2.8 mg/dl, 
most likely related to liver hypoperfusion, and ele- 
vated right atrial pressure (20.1 __ 6.4 mm Hg). At 
baseline, no difference was apparent between pa- 
tients who survived and those who died during 
LVAD support (Fig. 5). During support, however, 
the bilirubin value returned to normal in survivors 
and rose in those who had hepatorenal dysfunction 
and died. Also, the aspartate aminotransferase level 
was elevated at baseline (in part because of recent 
myocardial infarction in some patients) and re- 
turned to normal in survivors (Fig. 5). 
Renal dysfunction was also common before and 
after LVAD insertion. A statistically significant dif- 
ference (p = 0.01) was noted at baseline in blood 
urea nitrogen values between survivors and those 
who died (Fig. 6). Also, serum creatinine concentra- 
tion was significantly higher (p = 0.02) in the 
patients who died (Fig. 6). Three patients who 
survived became anuric in the early post-LVAD 
period and were treated with hemodialysis. Urine 
output returned from 3 to 6 weeks after LVAD 
insertion and the patients were withdrawn from 
dialysis. Mild elevations in blood urea nitrogen and 
creatinine values after dialysis was stopped in these 
patients are reflected in the late increases een in 
Fig. 6. All three patients continued with stable renal 
function, without dialysis, after heart transplanta- 
tion. Although a significant difference in blood urea 
nitrogen and creatinine l vels at baseline was noted 
between survivors and nonsurvivors, the difference 
was not specific. Three patients urvived who had a 
blood urea nitrogen value greater than 50 mg/dl, 
similar to the nonsurvivor group. 
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Fig. 3. The transpulmonary gradient (mean PA pressure minus mean LA pressure) rose after insertion of 
the device (p = 0.046). This was thought to be due to the effects of cardiopulmonary bypass and blood 
product administration. The transpulmonary gradient graduaUy decreased after this as the patient 
recovered from the operation (24 hours) and was not significantly different from baseline at the time of 
device explantation. TPG, Transpulmonary gradient; PA, pulmonary artery; LA, left atrium; N.S., Not 
significant. 
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Fig. 4. The right heart was markedly dilated in these patients, decreased with the initiation of LVAD 
support, and decreased further by the time of device explantation. Changes were seen in both the right 
ventricular end-diastolic volume (RVEDV) and end-systolic volume (RVESV), and the difference between 
the two represents right ventricular stroke volume. 
Along with hemodynamic and physiologic im- 
provements, all patients were actively motivated to 
regain muscle strength and physical conditioning. 
All patients were in New York Heart Association 
functional class I or II before transplantation. Pa- 
tients were temporarily inactivated on the transplant 
waiting list until they were out of the intensive care 
unit, physically active, and had regained near nor- 
mal renal and hepatic function. Daily exercise on a 
treadmill was recorded and reflects the steadily 
improving condition of these patients (Fig. 7). 
No thromboembolic events occurred in these 
patients despite a conservative anticoagulation reg- 
imen consisting of (at most) antiplatelet agents. The 
total number of patient-days of LVAD support was 
1583 days. No device failures occurred. Among the 
76% of patients undergoing transplantation verall, 
there was 100% survival after transplantation, and 
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Fig. 5. Measures of liver function such as total bilirubin and aspartate aminotransferase (AST) levels were 
elevated at baseline. Both bilirubin and aspartate aminotransferase returned to normal evels in patients 
who were survivors and were underwent transplantation. There was an increase, especially notable in the 
total bilirubin levels, in patients who died. There was no significant difference at baseline between patients 
who were survivors and those who were nonsurvivors. 
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Fig. 6. Measures of renal function, blood urea nitrogen (BUN) and serum creatinine (Scr), were generally 
elevated before device insertion. The levels for the patients who died were significantly higher for both 
blood urea nitrogen (p -- 0.01) and serum creatinine (p = 0.02). For patients who survived and underwent 
transplantation, blood urea nitrogen and creatinine generally returned to normal. Inasmuch as three 
survivors were removed from long-term dialysis with the recovery of renal function, a slight increase in 
blood urea nitrogen and serum creatinine were seen late. 
22 
all patients are in New York Heart Association 
functional class I. 
Discussion 
Developments in mechanical ¢irculatory support 
over the past decade bode well for the future 
application of such devi¢es for patients with end- 
stage heart disease. Univentricular support with an 
LVAD was shown to be feasible for most patients 
awaiting heart ransplantation, % 8 with generally bet- 
ter results than those obtained with a total artificial 
heart.4, lo Oc¢asional patients supported with an 
implantable LVAD, however, need at least tempo- 
rary right ventricular mechanical support (16% in 
our series), and we have been unable preoperatively 
to predi¢t which patients are at risk for early right 
heart failure. 2'4' 8 Preoperative measurements of 
right ventricular contractility and afterload are not 
good predictors because of poor specificity. Only 
one of our five patients with a right ventricular 
ejection fraction less than 10% (range 3% to 9%) 
and one of our five patients with a pre-LVAD 
pulmonary vascular esistance greater than 7 Wood 
units (range 7 to 10 Wood units) required an 
RVAD. 
Although most investigators agree that increased 
right ventricular afterload is the most important 
determinant of right heart failure, many other fac- 
tors also contribute. The Fontan operation physiol- 
ogy was observed in several patients during periods 
of ventricular tachycardia. With loss of right ventric- 
ular contractility, LVAD flow decreased to 3.5 to 4.0 
L/min. This is the same flow obtained by our patient 
with chronic right heart failure during attempts to 
wean the patient from the inotropic drugs support- 
ing right ventricular contractility. Therefore, right 
ventricular afterload and contractility are important 
to obtain optimal LVAD flow and patient rehabili- 
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Fig. 7. Treadmill distance during daily exercise indicated 
the steadily improving physical condition of patients re- 
ceiving long-term support. Shortly after patients left the 
intensive care unit, levels of activity were low, but they 
steadily increased as the patients returned to bettet 
physical condition before transplantation. 
tation. Until we develop consistent criteria to pre- 
operatively predict post-LVAD need for right ven- 
tricular mechanical support, we will continue to 
apply just LVAD support despite apparently high 
pulmonary vascular esistance and low right ventric- 
ular contractility. 
Preoperative blood urea nitrogen and creatinine 
levels were significantly higher in the nonsurvivor 
group by univariate analysis (the number of deaths 
was too small for multivariate analysis). Preopera- 
tive blood urea nitrogen elevation (but not creati- 
nine) was also identified by the Thoratec investiga- 
tors as a risk factor for death. 11 The FDA criteria for 
insertion of a HeartMate device allow use of the 
device if the blood urea nitrogen level is 100 mg/dl 
or less. We agree with others TM 12 that rising blood 
urea nitrogen levels should be considered a relative 
contraindication to LVAD insertion. However, such 
elevations are not a certain predictor of failure, 
inasmuch as three of our 19 survivors had a blood 
urea nitrogen level of 50 mg/dl or more before 
LVAD insertion. Therefore, we do not hesitate to 
proceed if blood urea nitrogen elevation is the only 
contraindication to LVAD insertion. Also, to help 
preserve renal and other organ function in patients 
with acute profound heart failure, we have used a 
heparin-coated ECMO system while transplantation 
evaluation is started. Although survival with ECMO 
as a "bridge-to-bridge" has been satisfactory (71%), 
the patients area high-risk group. Two of the five 
survivors of ECMO to LVAD to transplantation 
were anuric while receiving temporary hemodialysis. 
Multiple organ failure, specifically the combina- 
tion of renal and hepatic failure, has been the 
contributing cause of death for most of our patients. 
We do not yet have enough patient numbers to be 
able to predict which patients will have this frustrat- 
ing complication, despite adequate LVAD flow. 
Perhaps more aggressive use of perioperative dialy- 
sis, ECMO, and even temporary extracorporeal 
hepatic support 13 will allow us to save more of these 
patients. 
The ultimate goal of the implantable LVAD 
program, however, is not to salvage moribund pa- 
tients. The hemodynamic and physiologic findings in 
this report and others 2'9' a4, 15 suggest hat most 
stable patients with New York Heart Association 
class IV heart failure who receive these devices 
should have marked symptomatic improvement. 
With a remarkably low risk of thromboemboli (none 
in more than 4 patient-years of experience in this 
series), many of the previous impediments to 
chronic circulatory support have been addressed. 
Our studies already indicate that hospitalized pa- 
tients with the HeartMate LVAD experience a 
quality of life similar to that of patients who have 
had heart transplantation. 16 The portable vented 
electric HeartMate device designed by Poirier, and 
first used by Frazier, 17 should further improve qual- 
ity of life and allow patients to be discharged. As we 
embark on a new phase of outpatient mechanical 
support instead of heart transplantation, new issues, 
such as device durability, failure modes, and the risk 
of chronic device infection, will assume more impor- 
tance. More extensive clinical studies with the por- 
table outpatient LVAD is a necessary next step to 
address these issues and unmask other problems 
that cannot be identified with the bridge to trans- 
plantation experience. The hemodynamic and phys- 
iologic effectiveness of the implantable LVAD has 
been established in the bridge to heart transplanta- 
tion experience. 
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Discussion 
Dr. Walter P. Dembitsky (San Diego, Caliß). We art 
interested in the exercise capacity of patients in whom the 
HeartMate LVAD was implanted. We thought hat right 
ventricular function was the function defining the upper 
limit. Thus, using Swan-Ganz catheters (Baxter Health- 
care Corp., Edwards Division, Santa Ana, Calif) and 
echocardiograms, we studied (and reported on) four 
patients with implanted LVADs, eneouraging them to 
exercise to anaerobic thresholds. We found that left 
ventricular performance actually determined exercise ca- 
pacity. At high levels of exercise the recovered left ven- 
tricle began to eject in parallel with the pump. It contrib- 
uted significantly to the cardiac output. We also measured 
oxygen consumptions in the range of 15 to 20 ml/min. 
Have you noticed the degree of ventricular recovery on 
the left side with these implanted LVADs? Have you 
measured oxygen consumptions during exercise? 
Dr. MeCarthy. We studied left ventricular ffactional 
shortening, which was only 7% at the time of LVAD 
implantation. It did not rise significantly, being only 10% 
and 11% after LVAD insertion and at LVAD explanta- 
tion. We have noticed individual patients who appear to 
have more significant recovery. In general, however, we do 
not think that there will be significant recovery in most 
patients with ischemic ardiomyopathy. 
I did not present he limited data that we have on 
oxygen consumption because the measurements were 
made early after the patients received the devices. We 
have measured maximum oxygen consumption in the 
range of 15 ml/min. However, I am aware of data from the 
Texas Heart Institute showing that patients undergoing a 
longer duration of support have a further increase in 
oxygen consumption; one patient in The Netherlands 
reached an oxygen consumption of more than 30 tal/min 
during support. One advantage of the LVAD over the 
total artificial heart is that the patients with an LVAD will 
be able to have some contribution to total cardiac output 
from the native heart, and therefore a higher oxygen 
consumption. 
Dr. Nelson A. Burton (Annandale, Va.). We have had a 
similar experience at Fairfax Hospital over the past 4 
years having implanted the TCI HeartMate LVAD in 15 
heart ransplant candidates who were moribund and near 
death. Fourteen of these patients received the pneumatic 
device and one the portable electric LVAD. Three pa- 
tients were only 14 years of age. We have previously 
presented our hemodynamic data, which is nearly identi- 
cal to yours, and have been very impressed with the 
hemodynamic capability of the HeartMate LVAD. We 
have also been impressed with the fact that no thrombo- 
embolic events have occurred in more than 1000 patient- 
days of support, an average of more than 60 days of 
support per patient, maintained on minimal anticoagula- 
tion. One patient who received the nontethered electric 
device was supported for nearly 6 months. Twelve of the 
15 had successful transplantation a d all 12 are alive 3 
months to 4 years after cardiac transplantation. 
For anticoagulation with the electric device, we used 
warfarin sodium (Coumadin) instead of low-dose aspirin, 
which we use for pneumatic devices. Given the report at 
this meeting by Dr. Clark about microscopic emboli 
detected by transcranial Doppler studies during cardio- 
pulmonary bypass, as well as a report from the group at 
Columbia showing increased transcranial Doppler signals 
in patients while supported by the TCI LVAD, should we 
use additional anticoagulation for long-term LVAD sup- 
port? Should we consider using low-dose warfarin or some 
additional anticoagulation for patients in whom this de- 
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vice may be implanted for a period of years rather than 
months? 
Dr. MeCarthy. The only patient o whom I adminis- 
tered warfarin sodium was a patient with a large left 
ventricular aneurysm filled with thrombus who received 
a vented electric HeartMate LVAD last month. He had 
no emboli before successful transplantation after 30 
days of support. The source of emboli s not just from 
within the device, but also from within the patient's own 
heart, the aorta, or from prosthetic valves. In terms of 
the HeartMate device, whether it is used for short-term 
or long-term support, I do not think that the patients 
need to be given warfarin. Today, we give the patients 
only one aspirin a day. I think that it may be reasonable 
to administer warfarin to the unusual patient who is at 
risk for clot formation within the native heart, such as 
the patient with an aneurysm or a very large, dilated 
heart. 
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